EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Pirfenidone as a Novel Radioprotectant for Radiation-induced Intestinal Injury

Hiroshi Doi, Saori Tatsuno Imamura, Toshiyuki Minami, Yukinori Matsuo

Anticancer Research · 2026

DOI: 10.21873/anticanres.18388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Hiroshi Doi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Kindai University Faculty of Medicine, Sakai, Japan; hiroshidoi@wakayama-med.ac.jp. Hauptthemen laut MEDLINE: Radiation-Protective Agents, Pyridones, Radiation Injuries, Experimental, Intestines.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: The objective of this study was to investigate the radioprotective and radiomitigative effects of pirfenidone (PFD), a clinically approved drug used for the treatment of idiopathic pulmonary fibrosis, in a mouse model of radiation-induced intestinal injury. MATERIALS AND METHODS: Male C57BL/6J mice (8 weeks old) received oral PFD (300 mg/kg) at specified time points relative to irradiation (IR). In experiment 1, the mice were divided into an IR + PFD group (PFD administered 6 h before IR) and an IR-alone group. Mice were irradiated with a dose of 10 Gy, and duodenal tissues were harvested 4 h later and evaluated by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining and immunohistochemistry for ataxia-telangiectasia mutated (ATM) and γH2AX. In experiment 2, intestinal crypt survival was assessed 3.5 days after 15-Gy IR in four groups: IR-alone; PFD administered 6 h before IR (PFD-pre); PFD administered 24 h after IR (PFD-post); and PFD administered before and after IR (PFD-pre/post). RESULTS: The number of TUNEL-positive cells per crypt was significantly lower in the IR + PFD group than in the IR-alone group (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Radiation-Protective AgentsPyridonesRadiation Injuries, ExperimentalIntestinesRadiation InjuriesAnimalsMaleMiceMice, Inbred C57BLAtaxia Telangiectasia Mutated ProteinsHistonesDNA DamageApoptosis

Stichwörter der Autor:innen

DNA damage responseRadioprotectantTGF-βpirfenidoneradiation-induced intestinal injury

Substanzen

Radiation-Protective AgentsPyridonespirfenidoneAtaxia Telangiectasia Mutated ProteinsHistones

Autor:innen und Institutionen

  • Department of Radiation Oncology, Kindai University Faculty of Medicine, Sakai, Japan; hiroshidoi@wakayama-med.ac.jp.
  • Department of Radiology, Wakayama Medical University, Wakayama, Japan.
  • Department of Radiation Oncology, Kindai University Faculty of Medicine, Sakai, Japan.
  • Department of Respiratory Medicine, Hyogo Medical University, Nishinomiya, Japan.

Zitieren

APA

Doi, H., Imamura, S. T., Minami, T., & Matsuo, Y. (2026). Evaluation of Pirfenidone as a Novel Radioprotectant for Radiation-induced Intestinal Injury. Anticancer Research. https://doi.org/10.21873/anticanres.18388

Vancouver

Doi H, Imamura ST, Minami T, Matsuo Y. Evaluation of Pirfenidone as a Novel Radioprotectant for Radiation-induced Intestinal Injury. Anticancer Research. 2026. doi:10.21873/anticanres.18388

BibTeX
@article{Doi2026,
  author = {Doi, Hiroshi and Imamura, Saori Tatsuno and Minami, Toshiyuki and Matsuo, Yukinori},
  title = {Evaluation of Pirfenidone as a Novel Radioprotectant for Radiation-induced Intestinal Injury},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18388}
}
Kostenlos starten →